問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital (在職)

更新時間：2023-09-19

吳尚殷Wu, Shang-Yin
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • wusy.tw@gmail.com

Recruiting Trial

268Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳尚殷

List

474Cases

2020-09-01 - 2028-12-31

Phase III

Active
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab) / JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2025-10-01 - 2029-12-31

Phase III

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Test Drug

    Subcutaneous injection Injection Injection Injection Injection

Participate Sites
7Sites

Recruiting7Sites

2022-01-31 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-11-01 - 2026-06-30

Phase III

Active
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure.

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab)JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting5Sites

Recruiting2Sites

Terminated1Sites

2019-11-01 - 2024-05-13

Phase II

Completed
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Erdafitinib

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting5Sites

Terminated6Sites

2018-10-30 - 2022-12-31

Phase III

Completed
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Erdafitinib

Participate Sites
12Sites

Recruiting2Sites

Terminated10Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2015-04-20 - 2019-12-31

Phase II

Completed
A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    JNJ-42756493(Erdafitinib)

Participate Sites
4Sites

Terminated4Sites

2020-09-01 - 2027-05-01

Phase I

Active
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372JNJ-73841937(lazertinib)

Participate Sites
5Sites

Recruiting5Sites

2022-08-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2020-12-14 - 2024-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5 6 48
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB